Sign Out
Colourless, clear to slightly opalescent solution.
Each ml of concentrate contains 20 mg of natalizumab.
When diluted (see Special precautions for disposal and other handling under Cautions for Usage), the solution for infusion contains approximately 2.6 mg/ml of natalizumab.
Natalizumab is a recombinant humanised anti-α4-integrin antibody produced in a murine cell line by recombinant DNA technology.
Excipient with known effect: Each vial contains 2.3 mmol (or 52 mg) sodium (see Precautions for further information).
Excipients/Inactive Ingredients: Sodium phosphate, monobasic, monohydrate; Sodium phosphate, dibasic, heptahydrate; Sodium chloride; Polysorbate 80 (E433); Water for injections.
